Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/...vator in biotechnology for diabetes therapy, and a...ervices to food, supplement, biotechnology and pha...he previously reported $6.3 million registered dir...870 shares of its common stock and warrants to pur...
(Date:11/19/2009)...VERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswire/... Resources find that the leading driver of antibio... broad-spectrum activity against gram-positive and...ganisms that can cause nosocomial pneumonia, surve...arily for agents that provide appropriate coverage...
(Date:11/19/2009)... Top LASIK surgeons and recognized refracti...LASIK Surgeons made brought their fellow surgeons ...rrection surgery, cataract surgery, and ophthalmol...Academy of Ophthalmology (AAO) annual meeting in S...r. Shachar Tauber, Dr. David Huang, MD, Dr. Randy ...
(Date:11/19/2009)... VIENNA, Austria, November 19 AFFi...on one product candidate at an unexpectedly early,...s planned to enter into,Phase II clinical trial ea...ely follows the completion of two Phase I trials w...d its fast decision on the first interim,analysis ...
Breaking Biology Technology:Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...on Will be Webcast Live and Archived on Company,s ...cals,Inc. (Nasdaq: VNDA ), a biopharmaceutical co...tion of clinical-stage product candidates for cent... the company will deliver a,corporate presentation...me., The presentation will take place as part of ...
... May 8 /PRNewswire-FirstCall/ - Angiotech Pharmace...specialty pharmaceutical and,medical device compan...ica,2008 Health Care Conference, which is being he...nter, Angiotech,s President and Chief Executive Of..., beginning at approximately,4:00 pm Pacific Time....
..., May 8 Applied Isotope Technologies ("AIT"),anno...Discovery Products,will be exclusively used for th...etabolic biochemical assessment when they are plac...ucted at The Children,s Institute,in Pittsburgh, P...m,Disorders (ASD) will lead a team of scientists f...
Other Biology Technology:Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism 2
(Date:11/19/2009)... This week, scientists are revealing the genetic ...eal crops. Corn, or maize, has one of the most com...ty of Wisconsin-Madison genomicist David Schwartz,...le in the journal Science . , "The maize genome...d-ends that have troubled would-be sequencers for ...
(Date:11/19/2009)... comes to corn, 1 + 1 = more than 2: The offspring... of their parents. Characterizing the gene-level v... heterosis or hybrid vigor, could boost our abilit... as high protein content for human consumption or ...elp from the newly released DNA sequence of the co...
(Date:11/19/2009)...ssive survey of genetic diversity in maize, also k..., have developed a gene map that should pave the w...a major source of food, fuel, animal feed and fibe...e of gene map known as a haplotype map, charts gen... of 27 inbred lines of maize. The research team, l...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2JCI table of contents 3A Oct 19 2009 59769 1JCI table of contents 3A Oct 19 2009 59769 2JCI table of contents 3A Oct 19 2009 59769 3Research with wood ducks earns graduate student 2 national awards 10420 1Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 1Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 2Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 3
...n Australia have discovered that cane toads are fa...at ants than native frogs. Their research publish...nctional Ecology reveals a chink in the cane toa...his alien invasive species in tropical Australia. ... Ward-Fear, Matt Greenlees and Greg Brown from the...
...ch 30, 2009 In an international human genetic stu...have identified a gene linked to the autoimmune di...might help explain why females are 10 times more s...ng this gene, IRAK1, as a disease gene may also ha...n, professor of internal medicine and senior autho...
... to animals of omega 3 fatty acids in fish oils ha...culatory system, improving meat quality and reduci...ay only apply to cows but lowering emissions is im...by farm animals is a major contribution to greenho...s from University College Dublin reported that by ...
Other Biology News:Aussie meat ants may be invasive cane toad's Achilles' heel 2Gene linked to lupus might explain gender difference in disease risk 2
Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
...r RNA aptamer screening and binding optimization a...ofluidic on-chip synthesis platform. These microar...A/RNA Aptamer Microarray Service. Probe Content ...s greater than 1500 known aptamer sequences. Add u...
Biology Products: